Intravitreal autologous CD34+ cells for Retinitis Pigmentosa

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Retinitis Pigmentosa+1 More
Intravitreal autologous CD34+ cells - Biological
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test whether it is safe to give participants with retinitis pigmentosa an injection of their own stem cells in order to improve their vision.

Eligible Conditions
  • Retinitis Pigmentosa

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 5 Secondary · Reporting Duration: 6 months

1 month
Best corrected visual acuity
Electroretinography
Microperimetry
National Eye Institute Vision Questionnaire
Visual Field
6 months
Safety of intravitreal injection of autologous CD34+ cells
Baseline
Feasibility of intravitreal injection of autologous CD34+ cells

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Intravitreal autologous CD34+ cells
1 of 1
Experimental Treatment

4 Total Participants · 1 Treatment Group

Primary Treatment: Intravitreal autologous CD34+ cells · No Placebo Group · Phase 1

Intravitreal autologous CD34+ cells
Biological
Experimental Group · 1 Intervention: Intravitreal autologous CD34+ cells · Intervention Types: Biological

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 6 months

Who is running the clinical trial?

University of California, DavisLead Sponsor
838 Previous Clinical Trials
5,002,884 Total Patients Enrolled
2 Trials studying Retinitis Pigmentosa
453 Patients Enrolled for Retinitis Pigmentosa
Cures Within ReachOTHER
18 Previous Clinical Trials
1,697 Total Patients Enrolled
1 Trials studying Retinitis Pigmentosa
12 Patients Enrolled for Retinitis Pigmentosa
Susanna Park, MD PhD3.18 ReviewsPrincipal Investigator - University of California, Davis
University of California, Davis
5Patient Review
Dr. Park is an excellent surgeon who saved my 3 year old daughter's life by performing surgery on her retin to remove cancer.

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 6th, 2021

Last Reviewed: October 19th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

Who else is applying?

What state do they live in?
Florida66.7%
Idaho33.3%
How old are they?
18 - 65100.0%
What site did they apply to?
University of California Davis100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%